[1. ASRANI S., DEVARBHAVI H., EATON J., KAMATH P. Burden of liver diseases in the world. J Hepatol. 2019; 70(1):151–171.10.1016/j.jhep.2018.09.01430266282]Search in Google Scholar
[2. PIMPIN L., CORTEZ-PINTO H., NEGRO F. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018; 69(3):718–735.10.1016/j.jhep.2018.05.01129777749]Search in Google Scholar
[3. CHEDID, M. Nonalcoholic Steatohepatitis: The Second Leading Indication for Liver Transplantation in the USA. Dig Dis Sci. 2017; 62:2621–2622.10.1007/s10620-017-4724-628840385]Search in Google Scholar
[4. DOYCHEVA I., WATT K., RIFAI G. Increasing Burden of Chronic Liver Disease Among Adolescents and Young Adults in the USA: A Silent Epidemic. Dig Dis Sci. 2017; 62(5):1373–1380.10.1007/s10620-017-4492-328194666]Search in Google Scholar
[5. HEIDELBAUGH J., BRUDERLY M. Cirrhosis and chronic liver failure: Part I. Diagnosis and evaluation. Am Fam Physician. 2006; 74(5):756–762.]Search in Google Scholar
[6. YOUNOSSI Z., STEPANOVA M., YOUNOSSI Y., GOLABI P., MISHRA A., RAFIQ N., et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020; 69:564–568.10.1136/gutjnl-2019-31881331366455]Search in Google Scholar
[7. SCHIERWAGEN R., USCHNER F., MAGDALENO F., KLEIN S.,TREBICKA J. Rationale for the use of statins in liver disease. Am J Physiol Liver Physiol. 2017; 312:407–412.10.1152/ajpgi.00441.201628280144]Search in Google Scholar
[8. MOCTEZUMA-VELAZQUEZ C., ABRALDES J., MONTANO-LOZA A. The Use of Statins in Patients with Chronic Liver Disease. Curr Treat Options Gastro. 2018; 16:226–240.10.1007/s11938-018-0180-429572618]Search in Google Scholar
[9. VARGAS J., ARRESE M., SHAH V., ARAB J. Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects. Curr Gastroenterol Rep. 2017; 19(9):43.10.1007/s11894-017-0584-7582268628752475]Search in Google Scholar
[10. JANICKO M., DRAZILOVA S., PELLA D., FEDACKO J., JERCUSKA P. Pleiotropic effects of statins in the diseases of the liver. World J Gastroenterol. 2016; 22(27):6201–6213.10.3748/wjg.v22.i27.6201494597927468210]Search in Google Scholar
[11. KUMAR S., GRACE N., QAMAR A. Statin Use in Patients with Cirrhosis: A Retrospective Cohort Study. Dig Dis Sci. 2104; 59:1958–1965.10.1007/s10620-014-3179-224838495]Search in Google Scholar
[12. SAKAMOTO K., KIMURA J. Mechanism of Statin-Induced Rhabdomyolysis. J Pharmacol Sci. 2013; 123:289–294.10.1254/jphs.13R06CP24257439]Search in Google Scholar
[13. FARIGON, S., PORZIO, M., FRACANZANI A. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World J Gastroenterol. 2014; 20(37)13306–13324.10.3748/wjg.v20.i37.13306418888825309067]Search in Google Scholar
[14. DONGIOVANNI P., PETTA A., MANNISTRO V., MANCINA R., PIPITONE R., VALENTI L., et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. Journal of Hepatology. 2015; 63:705–712.10.1016/j.jhep.2015.05.00625980762]Search in Google Scholar
[15. IKEDA M., ABEK., YAMADA M., DANSAKO H., KATO N. Different anti-HCV profiles for statins and their potential for combination therapy with interferon. Hepatology. 2006; 44(1):117–125.10.1002/hep.2123216799963]Search in Google Scholar
[16. ABRALDES, J., VILLANUEVA C., ARACIL C., TURNES J., HERNANDEZ-GUERRA M., et a;. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterology. 2016; 150:1160–1170.10.1053/j.gastro.2016.01.00426774179]Search in Google Scholar
[17. SIMON T., BONILLA H., CHUNG R., BUTT A. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients hepatitis c virus: results from ERCHIVES. Hepatology. 2016; 64(1):47–57.10.1002/hep.28506491743826891205]Search in Google Scholar
[18. KAWATA S., YAMASAKI E., NAGASE T., INUI Y., ITO N., MATSUDA Y., et al. Effect of Pravastatin on Survival in Patients with Advanced Hepatocellular Carcinoma. A Randomized Control Trial.Br J Cancer. 2001; 84:886–891.10.1054/bjoc.2000.1716236383811286466]Search in Google Scholar
[19. CONNOLLY S. Evidence-based analysis of amiodarone efficacy and safety. Circulation. 1999; 100(19):2025.10.1161/01.CIR.100.19.202510556230]Search in Google Scholar
[20. BABATIN, M., LEE S., POLLAK P. Amiodarone Hepatotoxicity. Current Vascular Pharmacology. 2008; 6:228–236.10.2174/15701610878491201918673162]Search in Google Scholar
[21. POLLACK P., BOUILLON T., SHAFER S. Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther. 200; 67:642–652.10.1067/mcp.2000.10704710872646]Search in Google Scholar
[22. MATTAR W., GADUS-PIZLO I., KWO P. Amiodarone Hepatotoxicity in the Context of the Metabolic Syndrome and Right-sided Heart Failure. Gastrointestin Liver Dis. 2009; 18(4):419–423.]Search in Google Scholar
[23. PENDYALA V. A case of Amiodarone-induced Hepatitis and Review of the Literature. J Hepatol Gastroint Dis. 2016; 2:120.]Search in Google Scholar
[24. SUNG P., YOON S. Amiodarone Hepatotoxicity. Hepatology. 2012; 1:326.]Search in Google Scholar
[25. LEWIS J., RANARD R., CARUSO A., JACKSON L., MULLICK F., ISHAK K., et al. Amiodarone hepatotoxicity: prevalence and clincopathologic correlations among 104 patients. Hepatology. 1989; 9:679–685.10.1002/hep.18400905042785079]Search in Google Scholar
[26. ATIQ M., DAVIS J., LAMPS L., BLENAD S., ROSE L. Amiodarone induced liver cirrhosis, Report of two cases. J Gastrointestin Liver Dis. 2009; 18:233–235.]Search in Google Scholar
[27. GOLDSCHLAGER N., EPSTEIN A., NACCARELLI G., OLSHANSKY B., SINGHB. Practical guidelines for clinicians who treat patients with amiodarone. Practice guidelines subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med. 2000; 160:1741–1748.10.1001/archinte.160.12.174110871966]Search in Google Scholar
[28. KUM L., CHAN W., HUI H., WONG G., HO S., SANDERSON J., et al. Prevalence of amiodarone-related hepatotoxicity in 720 Chinese Patients with or without baseline liver dysfunction. Clin Cardiol. 2006; 29:295–299.10.1002/clc.4960290705665391216881537]Search in Google Scholar
[29. TRIPODI A., MUNUCCIP. The coagulopathy of chronic liver disease. N Engl J Med. 2011; 365:147–156.10.1056/NEJMra101117021751907]Search in Google Scholar
[30. QAMAR A., VADUGANATHAN M., GREENBERGER N., GIUGLIANO R. Oral anticoagulants in patients with liver disease. JAM Coll Cardiol. 2018; 71(19)2162–2175.10.1016/j.jacc.2018.03.02329747837]Search in Google Scholar
[31. LING K., CHAO T., LIU C., LIN Y., CHANG S., LO L., HU Y., TUAN, T., et al. Liver cirrhosis in patient with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention? J Am Herat Assoc. 2017; 6(6).10.1161/JAHA.116.005307566916228645935]Search in Google Scholar
[32. GORIACKO P. VELTRI K. Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation. Eur J Haematol. 2018; 100(5):488–493.10.1111/ejh.1304529444357]Search in Google Scholar
[33. HUM J., SHATZEL J., JOU J., DELOUGHERY T. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol. 2017; 98:393–397.10.1111/ejh.1284428009449]Search in Google Scholar
[34. INTAGLIATA N., HENRY Z., MAITLAND H., SHAH N., MATILANDS H., SHAH N., ARGO C., NORTHUP P., CALDWELL S. Direct oral anticoagulants in cirrhosis patient pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci. 2016; 61:1721–1727.10.1007/s10620-015-4012-226725062]Search in Google Scholar
[35. MALESPIN M. Risk of nonsteroidal anti-inflammatory drugs and safety of acetaminophen in patients with advanced liver disease. Clin Liver Dis. 2018; 12(3):85–88.10.1002/cld.737638591330988918]Search in Google Scholar
[36. CHANDOK N., WATT K. Pain management in the cirrhotic patient: The clinical challenge. Mayo Clin Proc. 2010; 85(5):451–458.10.4065/mcp.2009.0534286197520357277]Search in Google Scholar
[37. Eliquis (apixaban) [package insert]. Bristol-Myers Squibb. New York, NY; 11/2019. [cited May 14/2020]. Available from: http://packageinserts.bms.com/pi/pi_eliquis.pdf.]Search in Google Scholar
[38. Pradaxa (dabigatran etexilate) [package insert]. Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield, CT; 11/2019 [cited May 14, 2020]. Available from: https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf.]Search in Google Scholar
[39. Savaysa (edoxaban) [package insert]. Daiichi Sankyo. Tokyo, Japan. 1/2015 [cited May 14/2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf.]Search in Google Scholar
[40. Xarelto (rivaroxaban) [package insert]. Janssen Pharmaceuticals Inc. Titusville, NJ; 03/2020 [cited May 14/2020]. Available from: https://www.xareltohcp.com/shared/product/xarelto/prescribing-information.]Search in Google Scholar